<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33427561</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>RNA biology</Title><ISOAbbreviation>RNA Biol</ISOAbbreviation></Journal><ArticleTitle>Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy.</ArticleTitle><Pagination><StartPage>1546</StartPage><EndPage>1554</EndPage><MedlinePgn>1546-1554</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15476286.2020.1860580</ELocationID><Abstract><AbstractText>Pathological changes involving TDP-43 protein ('TDP-43 proteinopathy') are typical for several neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD). FTLD-TDP cases are characterized by increased binding of TDP-43 to an abundant lncRNA, NEAT1, in the cortex. However it is unclear whether enhanced TDP-43-NEAT1 interaction represents a protective mechanism. We show&#xa0;that accumulation of human TDP-43 leads to upregulation of the constitutive NEAT1 isoform, NEAT1_1, in cultured cells and in the brains of transgenic mice. Further, we demonstrate that overexpression of NEAT1_1 ameliorates TDP-43 toxicity in <i>Drosophila</i> and yeast models of TDP-43 proteinopathy. Thus, NEAT1_1 upregulation may be protective in TDP-43 proteinopathies affecting the brain. Approaches to boost NEAT1_1 expression in the CNS may prove useful in the treatment of these conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsukawa</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukharsky</LastName><ForeName>Michail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medicinal and Biological Chemistry, Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sei-Kyoung</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Nevada, Reno, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sangeun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3898-6197</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, University of Nevada, Reno, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Naruaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebman</LastName><ForeName>Susan W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-5845-4633</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, University of Nevada, Reno, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelkovnikova</LastName><ForeName>Tatyana A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0003-1367-5309</Identifier><AffiliationInfo><Affiliation>Medicines Discovery Institute, School of Biosciences, Cardiff University, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MRF_MRF-060-0001-RG-SHELK</GrantID><Acronym>MRF</Acronym><Agency>MRF</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R35 GM136229</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SHELKOVNIKOVA/OCT17/968-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>RNA Biol</MedlineTA><NlmUniqueID>101235328</NlmUniqueID><ISSNLinking>1547-6286</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577276">NEAT1 long non-coding RNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">NEAT1</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">drosophila</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">proteinopathy</Keyword><Keyword MajorTopicYN="N">yeast</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>11</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33427561</ArticleId><ArticleId IdType="pmc">PMC8583295</ArticleId><ArticleId IdType="doi">10.1080/15476286.2020.1860580</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ratti A, Buratti E.. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J Neurochem. 2016;138(Suppl 1):95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, Gendron TF, Zhang YJ, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Lee EB, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai KJ, Yang CH, Fang YH, et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med. 2010;207:1661&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916125</ArticleId><ArticleId IdType="pubmed">20660618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon A, Yang B, Knight J, et al. Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol. 2012;123:807&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359456</ArticleId><ArticleId IdType="pubmed">22539017</ArticleId></ArticleIdList></Reference><Reference><Citation>Renoux AJ, Todd PK. Neurodegeneration the RNA way. Prog Neurobiol. 2012;97:173&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582174</ArticleId><ArticleId IdType="pubmed">22079416</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox AH, Nakagawa S, Hirose T, et al. Paraspeckles: where long noncoding RNA meets phase separation. Trends Biochem Sci. 2018;43:124&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">29289458</ArticleId></ArticleIdList></Reference><Reference><Citation>An H, Williams NG, Shelkovnikova TA. NEAT1 and paraspeckles in neurodegenerative diseases: A missing lnc found? Noncoding RNA Res. 2018;3:243&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6257911</ArticleId><ArticleId IdType="pubmed">30533572</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler AA, Johnston DR, Kaur S, et al. Long noncoding RNA NEAT1 mediates neuronal histone methylation and age-related memory impairment. Sci Signal. 2019;12:eaaw9277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219525</ArticleId><ArticleId IdType="pubmed">31266852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky MS, Ninkina NN, An H, et al. Long non-coding RNA Neat1 regulates adaptive behavioural response to stress in mice. Transl Psychiatry. 2020;10:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256041</ArticleId><ArticleId IdType="pubmed">32467583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunwoo H, Dinger ME, Wilusz JE, et al. MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res. 2009;19:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661813</ArticleId><ArticleId IdType="pubmed">19106332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Hutt KR, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15:1488&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Modic M, Grosch M, Rot G, et al. Cross-regulation between TDP-43 and paraspeckles promotes pluripotency-differentiation transition. Mol Cell. 2019;74:951&#x2013;965 e913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561722</ArticleId><ArticleId IdType="pubmed">31047794</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Naganuma T, Nakagawa S, Tanigawa A, et al. Alternative 3&#x2b9;-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. Embo J. 2012;31:4020&#x2013;4034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474925</ArticleId><ArticleId IdType="pubmed">22960638</ArticleId></ArticleIdList></Reference><Reference><Citation>West JA, Mito M, Kurosaka S, et al. Structural, super-resolution microscopy analysis of paraspeckle nuclear body organization. J Cell Biol. 2016;214:817&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5037409</ArticleId><ArticleId IdType="pubmed">27646274</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Kukharsky MS, An H, et al. Protective paraspeckle hyper-assembly downstream of TDP-43 loss of function in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984788</ArticleId><ArticleId IdType="pubmed">29859124</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto Y, Nakagawa S, Hirose T, et al. The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. Mol Brain. 2013;6:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729541</ArticleId><ArticleId IdType="pubmed">23835137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky MS, Quintiero A, Matsumoto T, et al. Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis. Mol Neurodegener. 2015;10:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428507</ArticleId><ArticleId IdType="pubmed">25888396</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Gitler AD, Lindquist S. A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast. 2007;24:913&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190539</ArticleId><ArticleId IdType="pubmed">17583893</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SK, Park S, Liebman SW. Respiration enhances TDP-43 toxicity, but TDP-43 retains some toxicity in the absence of respiration. J Mol Biol. 2019;431:2050&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502655</ArticleId><ArticleId IdType="pubmed">30905713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara R, Matsukawa K, Nagata Y, et al. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Hum Mol Genet. 2013;22:4474&#x2013;4484.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804749</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto T, Matsukawa K, Watanabe N, et al. Self-assembly of FUS through its low-complexity domain contributes to neurodegeneration. Hum Mol Genet. 2018;27:1353&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">29425337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:125&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki YT, Ideue T, Sano M, et al. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci U S A. 2009;106:2525&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650297</ArticleId><ArticleId IdType="pubmed">19188602</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Harvey AR, Hodgetts SI, et al. Functional dissection of NEAT1 using genome editing reveals substantial localisation of the NEAT1_1 isoform outside paraspeckles. RNA. 2017;23:872&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435860</ArticleId><ArticleId IdType="pubmed">28325845</ArticleId></ArticleIdList></Reference><Reference><Citation>An H, Skelt L, Notaro A, et al. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun. 2019;7:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Naganuma T, Shioi G, et al. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. J Cell Biol. 2011;193:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082198</ArticleId><ArticleId IdType="pubmed">21444682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluthgen N, van Bentum M, Merz B, et al. Profiling the MAPK/ERK dependent and independent activity regulated transcriptional programs in the murine hippocampus in vivo. Sci Rep. 2017;7:45101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5368636</ArticleId><ArticleId IdType="pubmed">28349920</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Valdmanis P, Millecamps S, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle JG, Lanson NA Jr., Smith RB, et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet. 2013;22:1193&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578413</ArticleId><ArticleId IdType="pubmed">23257289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D&#x2019;Ambrogio A, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, Paunesku T, Woloschak GE, et al. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007;114:81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569064</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, Higgins MJ, Figley MD, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet. 2012;44:1302&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A, Herholz D, Fiesel FC, et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PloS One. 2010;5:e12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Li X, Malik AM, et al. An intramolecular salt bridge linking TDP43 RNA binding, protein stability, and TDP43-dependent neurodegeneration. Cell Rep. 2019;27:1133&#x2013;1150 e1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499398</ArticleId><ArticleId IdType="pubmed">31018129</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Sivakumar P, Humphrey J, et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. Embo J. 2018;37. DOI:10.15252/embj.201798684</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338 e328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Berson A, Kennerdell JR, et al. Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. Nat Commun. 2018;9:4406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199344</ArticleId><ArticleId IdType="pubmed">30353006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Piccolo L, Bonaccorso R, Attardi A, et al. Loss of ISWI function in drosophila nuclear bodies drives cytoplasmic redistribution of drosophila TDP-43. Int J Mol Sci. 2018;19:1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5979594</ArticleId><ArticleId IdType="pubmed">29617352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Piccolo L, Jantrapirom S, Nagai Y, et al. FUS toxicity is rescued by the modulation of lncRNA hsromega expression in Drosophila melanogaster. Sci Rep. 2017;7:15660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688078</ArticleId><ArticleId IdType="pubmed">29142303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu RK, Mutt E, Lakhotia SC . Conservation of gene architecture and domains amidst sequence divergence in the hsr&#x3c9; lncRNA gene across the Drosophila genus: an in silico analysis. J Genet. 2020;99:64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33622991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>